ABIONYX Pharma

Equities

ABNX

FR0012616852

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:35:24 2024-04-26 am EDT			5-day change	1st Jan Change
1.024 ^EUR	+0.59%		-4.66%	-20.50%

Mar. 14	Abionyx Pharma: to benefit from a 1ME grant from Bpifrance	CF
Mar. 11	Abionyx: reduced net loss in 2023	CF

ABIONYX Pharma Appoints Rob Scott as Chief Medical Officer and Head of R&D

January 08, 2024 at 01:23 pm EST

ABIONYX Pharma, announced the appointment of Dr. Rob Scott, former Chief Medical Officer and Head of Development at AbbVie, where he oversaw successful drug development for brands like Skyrizi, and Rinvoq, as Chief Medical Officer and Head of R&D with immediate effect. Dr. Rob Scott brings extensive clinical development and regulatory experience to ABIONYX Pharma.

Latest news about ABIONYX Pharma

Abionyx Pharma: to benefit from a 1ME grant from Bpifrance	Mar. 14	CF
Abionyx: reduced net loss in 2023	Mar. 11	CF
ABIONYX Pharma SA Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11	CI
Abionyx: CSL Behring fails in heart disease trial	Feb. 16	CF
ABIONYX Pharma SA Acknowledges the Clinical Results of the Phase 3 Aegis-Ii Study Evaluating the Efficacy and Safety of Csl Behring?S Human-Plasma-Derived Apoa-I, CSL112	Feb. 15	CI
Abionyx: former AbbVie executive appointed CMO	Jan. 09	CF
ABIONYX Pharma Appoints Rob Scott as Chief Medical Officer and Head of R&D	Jan. 08	CI
Abionyx: Successful completion of third GMP batch of CER-001	Dec. 19	CF
2,867,986 Ordinary Shares of ABIONYX Pharma SA are subject to a Lock-Up Agreement Ending on 7-DEC-2023.	Dec. 06	CI
Abionyx: encouraging results in brain fog	Nov. 24	CF
ABIONYX Pharma Presents Preclinical Results for CER-001 in Brain Fog, At the 1st International Scientific Congress on Brain-Kidney Interaction in Naples on November 23-24, 2023	Nov. 23	CI
Abionyx: promising new results in uveitis	Nov. 21	CF
ABIONYX Pharma Announces New Positive Results in a Uveitis Model for the Strategic Development of the First Class of Biomedicines in Ophthalmology Based on its Recombinant apoA-I	Nov. 21	CI
Abionyx: cash position reaches 1.7 million euros	Nov. 17	CF
Abionyx Pharma Racers Study Data in Sepsis Presented At the American Society of Nephrology 2023 Annual Meeting "Kidney Week"	Nov. 02	CI
Abionyx: presentation planned at ASN congress	23-10-16	CF
ABIONYX Pharma RACERS Study in Sepsis Selected for Late-Breaking Clinical Results Poster Presentation at the American Society of Nephrology 2023 Annual Meeting " Kidney Week"	23-10-16	CI
Abionyx Pharma: Cyrille Tupin below 5% of capital and voting rights	23-10-11	CF
Abionyx Pharma: capital increase completed	23-10-06	CF
Abionyx Pharma Raises EUR3 Million from Share Issue	23-10-06	MT
ABIONYX Pharma SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-26	CI
Abionyx: cash position of 1.9 million euros at the end of June	23-08-18	CF
ABIONYX Pharma Successfully Manufactures a Second Batch of Recombinant Human ApoA-I CER-001 Using a New, Innovative and Robust Industrial Bioprocess	23-07-26	CI
Abionyx: appointment of a chief digital & innovation officer	23-07-13	CF
Abionyx Pharma Names Digital, Innovation Chief	23-07-13	MT

Chart ABIONYX Pharma

Duration

Period

More charts

Company Profile

ABIONYX Pharma SA is specialized in research & development into HDL therapies (High Density lipoproteins) intended for the treatment of cardiovascular and metabolic disorders. HDLs, also known as good cholesterol, are fat and protein complexes that contribute to the transportation of cholesterol from the body's tissues to the liver and are linked to a decrease in the risk of atherosclerosis and coronary diseases. At the end of 2022, the company boasted a portfolio of 3 products in clinical development.

Sector

Biotechnology & Medical Research

Calendar

2024-05-15 - Q1 2024 Sales and Revenue Release

More about the company

Income Statement Evolution

More financial data

Ratings for ABIONYX Pharma

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.024 EUR

Average target price

10.5 EUR

Spread / Average Target

+925.39%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ABIONYX PHARMA	-20.50%	35.21M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs